GlobeNewswire by notified

Copenhagen Infrastructure Partners and Myrsky Energia to develop over 1.8 GW projects in Finland

Share

Copenhagen Infrastructure Partners (CIP), on behalf of its Flagship Funds, and Myrsky Energia (Myrsky) today announced a partnership to develop more than 1.8 GW of onshore wind power in Finland. This transaction puts Finland on track to become a European leader in the energy transition and will make a material contribution toward Finland’s 2035 carbon neutrality target.

COPENHAGEN, Denmark and HELSINKI, Finland, May 24, 2023 (GLOBE NEWSWIRE) -- CIP has entered into a framework agreement with Myrsky, a Finnish developer specialising in wind power, to develop more than 1.8 GW of onshore wind power in Finland. This capacity will make a material contribution to Finland’s 2035 carbon neutrality target.

The partnership is reflective of CIP's strategy to pursue investments which deliver the step change in scale and pace of development required to meet the ambitious targets set by governments. The portfolio of wind projects will not only contribute to Finland’s net zero ambition but also improve energy security and help strengthen communities and transform local economies through job creation and additional tax revenues.

This marks the first investment by CIP in onshore wind power in the Nordic countries.

Nischal Agarwal, Partner in CIP, said of the transaction: “We believe Finland has excellent conditions for large scale onshore wind projects and a significant ambition to decarbonise by 2035 and achieve energy security. We are pleased to partner with Myrsky who is a leading renewables developer in Finland and we look forward to our cooperation and combining our expertise to participate in Finland’s energy transition.”

Tuomas Candelin-Palmqvist, entrepreneur and founder of Myrsky, commented: “We are delighted to partner with CIP to accelerate the delivery of Myrsky’s wind power projects over the coming years. On a global scale, Finland has unique onshore wind energy potential to produce renewable electricity. Green energy investments can create industry-scale business opportunities, local welfare, and employment as well as boost our energy security. Renewable energy is the new welfare industry for Finland."

About Copenhagen Infrastructure Partners
Founded in 2012, Copenhagen Infrastructure Partners P/S (CIP) today is the world’s largest dedicated fund manager within greenfield renewable energy investments and a global leader in offshore wind. The funds managed by CIP focuses on investments in offshore and onshore wind, solar PV, biomass and energy-from-waste, transmission and distribution, reserve capacity, storage, advanced bioenergy, and Power-to-X.

CIP manages ten funds and has to date raised approximately EUR 19 billion for investments in energy and associated infrastructure from more than 140 international institutional investors. CIP has approximately 400 employees and 11 offices around the world. For more information, visit www.cip.com

About Myrsky Energia
Founded in 2020, Myrsky Energia has over a decade of experience and deep roots in the renewables sector in Finland. Myrsky is a leading renewables developer in wind and solar power and the company has over 5 GW of wind power and 2 GW of solar power under development.

Cooperation, local presence, and respect for the nature guide Myrsky’s operations. The company employs over 30 energy professionals and has three offices in Finland. For more information, visit www.myrsky.fi

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Brains Bioceutical Announces the Addition of Industry Veteran John Boshart to its Animal Health Division6.5.2024 12:00:00 CEST | Press release

VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Today marks a pivotal development for Brains Bioceutical Corp ("Brains Bio"), as it significantly strengthens its Veterinary Health Division. This enhancement is led by John Boshart, a distinguished figure in animal health with profound experience from his tenures at Pfizer Animal Health and Zoetis. His arrival signifies a strategic consolidation of talent and expertise aimed at redefining standards within the veterinary sector. Brains Bio’s Animal Health Division is empowered by the unique properties of its THC-free CBD API, which boasts an ultra-low detection limit of 0.000006%. This EU-GMP Certified API is pivotal in clinical and preclinical studies, including a Phase III Clinical Trial, highlighting its potential for therapeutic applications in veterinary medicine. The CBD API is supported by rigorous regulatory credentials, including ICH-Q7 compliance, an actively maintained EU Active Substance Master File (ASMF), and a

Fejl i indre værdi i Investeringsforeningen Sparinvest6.5.2024 11:47:47 CEST | pressemeddelelse

Det skal oplyses, at der den 3. maj i perioden 09:45 til 10:55, er sket en fejl i beregningen af indre værdi for nedenstående afdeling. Indre værdi for nedenstående afdeling har i perioden været undervurderet. OrderbookcodeAfdelingsnavnISINPåvirkningSPIUSGKLSparindex INDEX USA Growth KLDK0010298272-0,68% Eventuel henvendelse vedrørende denne meddelelse kan rettes til NPA.PM@nykredit.dk eller CRH@nykredit.dk. Med venlig hilsen ID-Sparinvest, Filial af Sparinvest S.A, Luxembourg Dirk Schulze

Prepayments, Realkredit Danmark A/S6.5.2024 11:12:01 CEST | Press release

To Nasdaq Copenhagen A/SExecutive Management Bernstorffsgade 40 DK-1577 København V www.rd.dk Telephone +45 7012 5300 6 May 2024 Company Announcement No 34/2024 Prepayments, Realkredit Danmark A/S Pursuant to §24 of the Capital Markets Act, Realkredit Danmark A/S hereby publishes prepayments as of Friday 3 May 2024. Please find the data in the attached file. The information will also be available on www.rd.dk. Yours sincerely The Executive Management Any additional questions should be addressed to Hella Gebhardt Rønnebæk, Chief Analyst, phone +45 4513 2068. Attachments Nr 34_Ekstraordinaere indfrielser_ukBilag til selskabsmeddelelse nr 34-2024

Ekstraordinære indfrielser, Realkredit Danmark A/S6.5.2024 11:12:01 CEST | pressemeddelelse

Til Nasdaq Copenhagen A/SDirektionen Bernstorffsgade 40 1577 København V www.rd.dk Telefon 7012 5300 6. maj 2024 Selskabsmeddelelse nummer 34/2024 Ekstraordinære indfrielser, Realkredit Danmark A/S I medfør af lov om kapitalmarkeder §24 oplyses hermed om ekstraordinære indfrielser vedrørende Realkredit Danmark A/S pr. fredag den 3. maj 2024. Oplysningerne fremgår af vedhæftede datafil. Oplysningerne vil desuden kunne ses på Realkredit Danmarks hjemmeside på www.rd.dk. For yderligere informationer om dataformat og –indhold henvises til Nasdaq Copenhagen A/S’s hjemmeside. Med venlig hilsen Direktionen Eventuel henvendelse kan rettes til chefanalytiker Hella Gebhardt Rønnebæk, 45 13 20 68. Vedhæftede filer Nr. 34_Ekstraordinaere indfrielser_dkBilag til selskabsmeddelelse nr 34-2024

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia6.5.2024 11:00:00 CEST | Press release

Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and multiple doses, meeting its primary safety endpoints and showed early signs of potential efficacy.1­ DMI is a common, irreversible complication of diabetic retinopathy (DR) that may lead to blindness.12,3,4­ It can develop when the light sensitive tissues of the central retina do not receive adequate blood supply over a longer time. There are currently no approved treatments for DMI. The current standard of care for advanced DR includes intravitreal anti-VEGF treatment or invasive laser treatment. However, some patients’ conditions progress despite this treatment.5 BI 764524 uses a novel mode of action by inhibiting the Sema3A pathway to re-vascularize ischemic areas and potentia

HiddenA line styled icon from Orion Icon Library.Eye